Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Biological Psychiatry
|
January 15, 2008
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort
Magnus Lekman, Gonzalo Laje, Dennis Charney, et al.
Biological Psychiatry
|
December 29, 2015
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, et al.
Biological Psychiatry
|
October 4, 2002
Preclinical models: status of basic research in depression
Eric J Nestler, Elizabeth Gould, Husseini Manji, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 9, 2021
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study
Rachel Ochs-Ross, Ewa Wajs, Ella J Daly, et al.
American Journal of Human Genetics
|
April 28, 2006
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment
Francis J McMahon, Silvia Buervenich, Dennis Charney, et al.
The American Journal of Psychiatry
|
May 22, 2019
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova, Ella J Daly, Madhukar Trivedi, et al.
Current Pharmaceutical Design
|
January 14, 2012
Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study
Gregor E Berger, Stephen J Wood, Margaret Ross, et al.
Archives of General Psychiatry
|
July 4, 2007
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression
Xian-Zhang Hu, A John Rush, Dennis Charney, et al.
Nature Reviews. Drug Discovery
|
March 3, 2007
How can drug discovery for psychiatric disorders be improved?
Yves Agid, György Buzsáki, David M Diamond, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3
Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Biological Psychiatry
|
January 15, 2008
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort
Magnus Lekman, Gonzalo Laje, Dennis Charney, et al.
Biological Psychiatry
|
December 29, 2015
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, et al.
Biological Psychiatry
|
October 4, 2002
Preclinical models: status of basic research in depression
Eric J Nestler, Elizabeth Gould, Husseini Manji, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 9, 2021
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study
Rachel Ochs-Ross, Ewa Wajs, Ella J Daly, et al.
American Journal of Human Genetics
|
April 28, 2006
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment
Francis J McMahon, Silvia Buervenich, Dennis Charney, et al.
The American Journal of Psychiatry
|
May 22, 2019
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova, Ella J Daly, Madhukar Trivedi, et al.
Current Pharmaceutical Design
|
January 14, 2012
Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study
Gregor E Berger, Stephen J Wood, Margaret Ross, et al.
Archives of General Psychiatry
|
July 4, 2007
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression
Xian-Zhang Hu, A John Rush, Dennis Charney, et al.
Nature Reviews. Drug Discovery
|
March 3, 2007
How can drug discovery for psychiatric disorders be improved?
Yves Agid, György Buzsáki, David M Diamond, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|
November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3
Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
Page
of 4